通过KDM6A酸化抑制PER2,从而使HNSCC中产生糖溶性脆弱性
Jun Chen1,2,3, Yikang Ji1,2,3, Xin Chen1,2,3
1Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
在Ser829的KDM6A酸化使这种瘤抑制剂在头癌中失活. 这种表观遗传修饰通过改变细胞代谢促进瘤生长,提供了潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- KDM6A是一种关键的瘤抑制剂,参与表观遗传调节.
- 它在头部和部状细胞癌 (HNSCC) 的特定调节机制尚不清楚.
研究的目的:
- 调查HNSCC中KDM6A活动的调控机制.
- 识别关键的翻译后修改及其功能后果.
主要方法:
- 临床样本的组织微阵列分析.
- 质谱和生物化学测试.
- 染色体分析和代谢分析.
主要成果:
- 氨酸829 (Ser829) 被确定为HNSCC中KDM6A的主要酸化部位.
- 在Ser829的CDK1-介导化导致KDM6A的核出口和失活.
- 化KDM6A (KDM6A-pSer829) 通过H3K27Me3依赖的PER2沉默驱动糖分类重编程.
- 这一过程促进了瘤在体外和体内生长.
结论:
- 翻译后的KDM6A修饰是HNSCC中代谢适应的关键调节者.
- 通过KDM6A酸化介导的表观遗传代谢轴代表了HNSCC的潜在治疗策略.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Abnormal Proliferation
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
